急性髓细胞白血病治疗预后的影响因素  

The influential factor of acute myeloid leukemia to prognostic therapy

作　　者：张志南[1] 申晓梅[1] 

机构地区：[1]哈尔滨242医院,150066

出　　处：《航空航天医药》2008年第1期12-13,共2页Aerospace Medicine

摘　　要：目的:进一步探讨急性髓细胞白血病(AML)预后的影响因素。方法:123例AML患者,年龄大于55岁的称为老年组,85例。另38例年龄小于55岁的作为年轻组。同时根据FAB协作组分型诊断标准进行分型。应用标准化疗方案即3d蒽环类药物加7d阿糖胞苷进行诱导缓解治疗,达临床完全缓解(CR)后给予大剂量阿糖胞苷(HDAC)加柔红霉素(D)和HDAC加米托蒽醌(M)交替强化治疗。结果:年轻组2年、4年预期无病生存(DFS)分别为72.54%、27.45%,老年组分别为15.62%、3.12%。其中M2,M3生存期长。结论:年龄、AML亚型的分类,对AML患者治疗预后的影响很大。当前的治疗方向,应当是针对不同患者,采取个体化的治疗。Objective： In order to study the influential factor of AML patients to prognostic therapy . Methods ：123 patients with AML in remission were subgroup, exceed 55 years old called older age- group,85 patients.The others 38 patients is lower than 55 years old named younger age- group. Simultaneously according to FAB diagnostic code to typing. Using standard chemotherapy regimen to inducer remission, after CR confer HDAC addition D and HDAC addition M intensification therapy alternately.Results： The DFS of younger age - group discern were 72.54% ,27.45% in the 2 and 4 year, the older age - group discern were 15.62% ,3.12% o M2 and M3 DFS were long. Conclusions： Years of age, hypotype of AML were tremendous influence of AML patients.Now the direction of treatments are individualization to different patients.

关 键 词：髓细胞白血病 无病生存率 影响因素 

分 类 号：R733.71[医药卫生—肿瘤]